Real-life observational study on niraparib in older patients with primary tubo-ovarian cancer: a focus on safety and efficacy
Our findings suggest that niraparib is safe and well-tolerated in aged ≥ 75 years. Concerns about toxicity should not preclude the enrollment of elderly patients in treatment regiments.
Authors
- Giovanni Scambia (ORCID: https://orcid.org/0000-0002-9503-9041)
- Giorgia Russo (ORCID: https://orcid.org/0009-0004-1233-9850)
- Serena Maria Boccia (ORCID: https://orcid.org/0009-0008-4677-469X)
- Ilary Ruscito (ORCID: https://orcid.org/0000-0002-2586-832X)
- Carolina Maria Sassu (ORCID: https://orcid.org/0000-0002-1702-5859)
- Matteo Bruno (ORCID: https://orcid.org/0000-0003-4372-4220)
- Filippo Maria Capomacchia (ORCID: https://orcid.org/0000-0002-5509-4193)
- Laura Vertechy (ORCID: https://orcid.org/0000-0002-1155-3888)
- Cláudia Marchetti (ORCID: https://orcid.org/0000-0001-7098-8956)
- Anna Fagotti (ORCID: https://orcid.org/0000-0001-5579-335X)
- Adriana Ionelia Apostol (ORCID: https://orcid.org/0009-0008-4614-9261)
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Agostino Gemelli University Polyclinic (IT)
Publication Details
- Journal
- International Journal of Clinical Oncology
- Published
- 2025-11-04
- DOI
- https://doi.org/10.1007/s10147-025-02914-y
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00